Days after Onyx Pharmaceuticals’ banner drug came through in a big Phase III trial, Amgen is laying off about 40% of the subsidiary’s staff, shedding roughly 300 workers amid widespread cuts around the industry.

…read more

Source: UPDATED: Amgen is canning 300 Onyx staffers, abandoning campus in the latest biopharma purge